Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide a Central/Eastern European Perspective. /
The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of prod...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2020
|
| Sorozat: | DIABETES THERAPY
11 No. 4 |
| doi: | 10.1007/s13300-020-00777-2 |
| mtmt: | 31210610 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/18719 |